Edition:
India

AbbVie Inc (ABBV.N)

ABBV.N on New York Stock Exchange

65.65USD
1:31am IST
Change (% chg)

$0.13 (+0.20%)
Prev Close
$65.52
Open
$65.52
Day's High
$66.06
Day's Low
$65.38
Volume
1,616,125
Avg. Vol
2,289,346
52-wk High
$68.12
52-wk Low
$55.10

ABBV.N

Chart for ABBV.N

About

AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology,... (more)

Overall

Beta: 1.53
Market Cap(Mil.): $104,411.10
Shares Outstanding(Mil.): 1,593.58
Dividend: 0.64
Yield (%): 3.91

Financials

  ABBV.N Industry Sector
P/E (TTM): 17.95 28.87 29.67
EPS (TTM): 3.65 -- --
ROI: 12.09 13.62 13.13
ROE: 138.75 14.52 14.27

BRIEF-Abbvie CEO Richard Gonzalez's FY 2016 total compensation was $21 mln

* CEO Richard Gonzalez's FY 2016 total compensation was $21.0 million versus $20.8 million in FY 2015 - sec filing

20 Mar 2017

BRIEF-Abbvie granted priority review in Japan for its investigational regimen of Glecaprevir

* Abbvie granted priority review in Japan for its investigational regimen of Glecaprevir/Pibrentasvir (G/P) for the treatment of all major genotypes of chronic hepatitis c

14 Mar 2017

BRIEF-Abbvie CEO Richard Gonzalez's total 2016 compensation was $21 mln vs. $20.8 mln in 2015

* CEO Richard Gonzalez's total 2016 compensation was $21 million versus $20.8 million in 2015 - sec filing

09 Mar 2017

BRIEF-Abbvie's CEO total 2016 compensation was $21 mln - SEC filing

* CFO William Chase's 2016 total compensation was $8.8 million versus $7.6 million in 2015

09 Mar 2017

TG Therapeutics' leukemia drug clears key study, shares pop

TG Therapeutics Inc said a combination of its experimental cancer drug, ublituximab, and approved treatment Imbruvica was found to be more effective in high-risk leukemia patients, compared with Imbruvica as a standalone therapy.

06 Mar 2017

UPDATE 3-TG Therapeutics' leukemia drug clears key study, shares pop

* Shares rise as much as nearly 117 pct to $11.60 (Adds details, updates shares)

06 Mar 2017

BRIEF-Enanta says CHMP gives positive opinion for AbbVie's hep C treatment for patients with genotype 1B

* Enanta announces CHMP grants positive opinion for an eight-week treatment option with Abbvie's Viekirax® (ombitasvir/paritaprevir/ritonavir tablets) + exviera® (dasabuvir tablets) for patients with genotype 1b chronic hepatitis c

27 Feb 2017

BRIEF-Abbvie receives CHMP positive opinion for eight-week treatment option with Viekirax

* Abbvie receives CHMP positive opinion for eight-week treatment option with Viekirax (ombitasvir/paritaprevir/ritonavir tablets) + Exviera (dasabuvir tablets) for patients with genotype 1b chronic hepatitis c

27 Feb 2017

Fitch Affirms Astrazeneca at 'A'; Stable Outlook

(The following statement was released by the rating agency) LONDON, February 22 (Fitch) Fitch Rating has affirmed UK-based pharmaceutical company AstraZeneca PLC's (AZ) Long-Term Issuer Default Rating (IDR) and senior unsecured rating at 'A'. The Outlook is Stable. The rating remains underpinned by AZ's leading position in the global pharmaceutical sector, supported by a business risk profile characterised by scale, diversification, and focus on innovation. The group is accelerating the dev

22 Feb 2017

BRIEF-Abbvie announces $5 bln increase to stock repurchase program

* Abbvie announces $5 billion increase to stock repurchase program Source text for Eikon: Further company coverage:

17 Feb 2017

More From Around the Web

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $125.90 -0.36
Pfizer Inc. (PFE.N) $34.29 -0.18
Novartis AG (NOVN.S) CHF74.15 +0.75
Merck & Co., Inc. (MRK.N) $63.28 -0.22
Roche Holding Ltd. (ROG.S) CHF252.60 +2.40
Roche Holding Ltd. (RO.S) CHF252.50 +2.00
Abbott Laboratories (ABT.N) $44.77 -0.04
Eli Lilly and Co (LLY.N) $84.42 +0.06
Sanofi SA (SASY.PA) €83.30 +0.53

Earnings vs. Estimates